Aclaris Therapeutics, Inc.
ACRS
$2.83
-$0.05-1.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -24.09% | -35.76% | -39.32% | -47.58% | -53.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.09% | -35.76% | -39.32% | -47.58% | -53.18% |
| Cost of Revenue | 1.70% | 24.66% | 12.11% | -40.60% | -92.49% |
| Gross Profit | -56.14% | -45.81% | -25.39% | 31.38% | 108.51% |
| SG&A Expenses | -13.83% | 13.34% | -10.30% | -32.27% | -20.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.17% | 21.17% | 3.83% | -39.01% | -64.20% |
| Operating Income | -76.29% | -33.62% | -10.25% | 31.70% | 67.63% |
| Income Before Tax | -92.64% | -40.44% | 10.96% | -5,096.56% | 74.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -92.64% | -40.44% | 10.96% | -6,375.65% | 74.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -92.64% | -40.44% | 10.96% | -6,375.65% | 74.07% |
| EBIT | -76.29% | -33.62% | -10.25% | 31.70% | 67.63% |
| EBITDA | -77.64% | -33.84% | -11.06% | 31.48% | 67.77% |
| EPS Basic | -12.14% | 18.30% | 48.28% | -4,724.29% | 74.27% |
| Normalized Basic EPS | -24.58% | 24.95% | 39.26% | 55.79% | 75.59% |
| EPS Diluted | -12.14% | 18.30% | 48.28% | -4,216.17% | 74.27% |
| Normalized Diluted EPS | -24.58% | 24.95% | 39.26% | 55.79% | 75.59% |
| Average Basic Shares Outstanding | 71.78% | 71.94% | 72.20% | 34.49% | 0.81% |
| Average Diluted Shares Outstanding | 71.78% | 71.94% | 72.20% | 34.49% | 0.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |